 |
|
|
| |
Integrated Safety Analysis of Daclatasvir Plus Sofosbuvir,
With or Without Ribavirin, in Patients With HCV Genotype 3 Infection
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco, CA
Bernstein D,1 Landis C,2 Lawitz E,3 Luetkemeyer A,4 Harris M,5 Bhore R,5 Swenson ES,6 Ackerman P,6 Rana K,6 Dieterich D7
1Hofstra North Shore-Long Island Jewish School of Medicine, Manhasset, NY; 2University of Washington School of Medicine, Seattle, WA; 3Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX;
4University of California and San Francisco General Hospital, San Francisco, CA; 5Bristol-Myers Squibb, Princeton, NJ; 6Bristol-Myers Squibb, Wallingford, CT; 7Icahn School of Medicine at Mount Sinai, New York, NY
|
| |
|
|
|
|
|
